International asset and currency allocation

AF Lee - Journal of Portfolio Management, 1987 - search.proquest.com
A demonstration was performed to establish that portfolios constructed on the basis of the
separation between assets and currencies can be expected to outperform portfolios that do not …

[PDF][PDF] A general strategy for creating “inactive-conformation” abl inhibitors

B Okram, A Nagle, FJ Adrián, C Lee, P Ren, X Wang… - Chemistry & biology, 2006 - cell.com
Kinase inhibitors that bind to the ATP cleft can be broadly classified into two groups: those
that bind exclusively to the ATP site with the kinase assuming a conformation otherwise …

A type-II kinase inhibitor capable of inhibiting the T315I “gatekeeper” mutant of Bcr-Abl

HG Choi, P Ren, F Adrian, F Sun, HS Lee… - Journal of medicinal …, 2010 - ACS Publications
The second generation of Bcr-Abl inhibitors nilotinib, dasatinib, and bosutinib developed to
override imatinib resistance are not active against the T315I “gatekeeper” mutation. Here we …

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

…, AG Li, RE Iacob, T Sim, J Powers, C Dierks, F Sun… - Nature, 2010 - nature.com
In an effort to find new pharmacological modalities to overcome resistance to ATP-binding-site
inhibitors of Bcr–Abl, we recently reported the discovery of GNF-2, a selective allosteric …

[HTML][HTML] A specific interferon (IFN)-stimulated response element of the distal HLA-G promoter binds IFN-regulatory factor 1 and mediates enhancement of this …

S Lefebvre, S Berrih-Aknin, F Adrian, P Moreau… - Journal of Biological …, 2001 - ASBMB
Type I interferons display a broad range of immunomodulatory functions. Interferon β increases
gene expression at the transcriptional level through binding of factors to the interferon-…

[PDF][PDF] Synthesis and target identification of hymenialdisine analogs

Y Wan, W Hur, CY Cho, Y Liu, FJ Adrian, O Lozach… - Chemistry & biology, 2004 - cell.com
Hymenialdisine (HMD) is a sponge-derived natural product kinase inhibitor with nanomolar
activity against CDKs, Mek1, GSK3β, and CK1 and micromolar activity against Chk1. In order …

[HTML][HTML] Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule

…, A Vassort, W Englaro, Y Li, V Patel, F Adrian… - Journal of Biological …, 2015 - ASBMB
Cancer-associated point mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2)
confer a neomorphic enzymatic activity: the reduction of α-ketoglutarate to d-2-hydroxyglutaric …

Discovery of GNF-5837, a selective TRK inhibitor with efficacy in rodent cancer tumor models

P Albaugh, Y Fan, Y Mi, F Sun, F Adrian… - ACS Medicinal …, 2012 - ACS Publications
Neurotrophins and their receptors (TRKs) play key roles in the development of the nervous
system and the maintenance of the neural network. Accumulating evidence points to their …

Ba/F3 cells and their use in kinase drug discovery

…, S Kim, X Gu, G Xia, F Adrián - Current opinion in …, 2007 - journals.lww.com
Ba/F3 cells are an increasingly popular tool in kinase drug discovery. The ability to test the
transforming capacity of newly identified kinase mutations, and to profile drug candidates and …

[HTML][HTML] Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression …

…, C Winter, V Richon, C Garcia-Escheverria, F Adrian… - PloS one, 2017 - journals.plos.org
Tumor cells display fundamental changes in metabolism and nutrient uptake in order to utilize
additional nutrient sources to meet their enhanced bioenergetic requirements. Glutamine (…